You are here: Industry Insights > Market News > NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

firstwordpharmaJuly 06, 2021

Tag: NPPA , Ibuprofen , ranitidine , carbamazepine

Favorites

India’s pharmaceutical pricing regulator has allowed a one-time price hike of 50% for ibuprofen, ranitidine and carbamazepine, Business Standard reported.

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

After the latest increase, the price of carbamazepine, a drug used to treat epilepsy, would range from Rs 1 to Rs 4.61 per tablet. The new price of ranitidine, an antacid, would be in the range of Rs 1 to Rs 2.43 per tablet or per ml of liquid, while the price of ibuprofen, an analgesic, would be 59 paise to Rs 1.04 per tablet.

The National Pharmaceutical Pricing Authority (NPPA) allowed the price hike during its meeting held on June 28.

Previous:Oncodesign Appoints Aline Aubertin as an Independent Director of the Board of Directors

Next:France's Sanofi expects Covid vaccine to be ready by December

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>